INFO LE FIGARO – A board of directors of the pharmaceutical laboratory was to approve, on Sunday evening, its entry into exclusive negotiations with the investment fund. Bpifrance will acquire a stake in its subsidiary Opella.
The Doliprane will pass under the American flag. Neither the political controversy sparked by the announcement of this project on October 11, nor the counter-offensive by PAI, the unsuccessful candidate for the takeover of Opella, the branch dedicated to non-prescription medicines of Sanofi, will have led the French laboratory to change your mind.
Sanofi’s board of directors was to meet this Sunday to confirm its entry into exclusive negotiations with the American fund CD&R. The laboratory had already announced on October 11 that it was favoring the latter to sell it 51% of this activity, valued at 15 billion euros by CD & R. Opella has a turnover of 5.2 billion (12% of Sanofi’s turnover) and employs 11,000 people worldwide. Now the negotiations are exclusive, indicating a higher level of commitment. This information will not be made public until Monday morning at 9 a.m., the company having to…
This article is reserved for subscribers. You have 80% left to discover.
Do you want to read more?
Unlock all items immediately. No commitment.
Already subscribed? Log in
Related News :